|
Jun 21
|
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
|
|
Jun 18
|
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
|
|
May 10
|
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
|
|
May 8
|
Orexo Q1 2024 Interim Report
|
|
Mar 22
|
Correction: Notice of Annual General Meeting of Orexo
|
|
Feb 12
|
Orexo and Sobi agree to advance feasibility study with AmorphOX
|
|
Feb 8
|
Orexo Interim Report Q4 2023, incl. Full Year Report
|
|
Nov 28
|
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose
|
|
Jul 18
|
Orexo Q2 2023 Interim Report
|